ERBB2 and cancer: In turn, the luminal B (ER and PR positive, HER2 positive or HER2 negative, with high Ki67) subtype is responsible for 10–20% of all cancer cases, has a higher relapse rate, proliferative index, and lower recurrence survival (4–6).